Cynata Therapeutics Limited
CYYNF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.68M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.68 Million |
|---|---|
| Enterprise Value | $1.78 Million |
| Earnings per Share | $-0.04 |
| Beta | 1.12 |
| Outstanding Shares | 238,031,000 |
Return
| Return on Equity | 4701.47% |
|---|---|
| Return on Assets | -1368.30% |
| Return on Invested Capital | 4866.78% |
Valuation & Multiples
| P/E Ratio | -0.28 |
|---|---|
| PEG | -2.25 |
| Price to Sales | - |
| Price to Book Ratio | -0.01 |
| Enterprise Value to Revenue | 0.95 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 30, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 25, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Cynata Therapeutics Limited
0CEO: Kilian Kelly
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mes...